ClinicalTrials.gg

Program

OPT101

A development code.

Its studies are mostly in Diabetes Mellitus, Type 1 · Sepsis, led by Op-T.

Furthest: phase 2, since Apr 14, 20254 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Op-T42 open or runningphase 2since Apr 14, 2025Oct 5, 2020May 31, 2027phase 2 · NCT06964087

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2020First study: phase 1 study in HealthyFirst studyNCT04589403 · 14 enrolled · United States
  2. Jun 9, 2022Phase 1 study in Diabetes Mellitus, Type 1NCT05428943 · 24 enrolled · United States
  3. Oct 28, 2024Phase 1 study in SepsisNCT06669403 · 26 planned · United States
  4. Apr 14, 2025Phase 2 study in Diabetes Mellitus, Type 1NCT06964087 · 72 planned · United States

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT06964087

TargetBeta

CD40LG →read by rule
“OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation.”study text, by rule · the study

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06964087Diabetes Mellitus, Type 1 · United States2RecruitingMay 31, 202772
NCT06669403Sepsis · United States1Not yet recruitingApr 202626
NCT05428943Diabetes Mellitus, Type 1 · United States1CompletedFeb 21, 202424
NCT04589403Healthy · United States1CompletedSep 27, 202114

How it is read

Names in the registry

  • “OPT101”, 4 entries

Codes read as this program: OPT101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.